Objectives: Using a prospective interrupted time series design, our goal was to determine whether a change in urine antibiotic susceptibility reporting from co-amoxiclav to cefalexin to community clinicians served by Southmead General Hospital led to a change in antibiotic prescribing.
Introduction
The wide variation in the community use of antibiotics across European countries is also seen within countries between individual community clinicians. 1 -5 Countries and primary care practices with high antibiotic use also have high antibiotic resistance. 1 -5 This relationship between antibiotic use and resistance has been shown with b-lactams and penicillin-non-susceptible streptococci, macrolides and erythromycin-non-susceptible Streptococcus pneumoniae, and quinolones and fluoroquinolone-resistant Escherichia coli. 5 This increasing community antibiotic resistance has highlighted the need to improve antimicrobial prescribing in primary care. 6 -8 Many countries have now undertaken advertising campaigns to encourage the public to ask for fewer antibiotics. 9 -11 Educating community clinicians about the importance of antibiotic resistance and encouraging them to target antibiotics appropriately has increased the effectiveness of the public campaign messages. 9,12 -14 Community clinicians' antibiotic prescribing could be influenced by many factors, including their training and peers' prescribing, public campaigns, specific educational workshops, antibiotic pharmaceutical meetings or advertising in journals. Systematic reviews have found that combinations of these interventions are more successful. 15, 16 # The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2011; 66: 1396 -1404 doi:10.1093/jac/dkr088 Advance Access publication 11 March 2011 Urine specimens are the most common specimen sent to the microbiology laboratory for culture, and an average general practitioner (GP) in England with 2000 patients will receive one urine antibiotic susceptibility report per week. 17 Reading and acting on these urine antibiotic susceptibility reports will influence a clinician's antibiotic prescribing for that episode of urinary tract infection (UTI) and may also influence their prescribing for future UTIs as well as other infections. Tan and McNulty 18 found that laboratory reporting of quinolone or cephalosporin susceptibilities for UTI by microbiology laboratories in England was associated with a 50% increase in reported prescribing of these antibiotics by GPs; the difference for nitrofurantoin was substantially larger. However, Tan and McNulty's study was not designed to determine whether the association between antibiotic reporting and use was causal or due to other laboratory influences such as guidelines or education, or that the microbiology laboratories selectively choose to report antibiotics that were more commonly used in their local community.
To determine whether the antibiotic susceptibilities reported on urine cultures influence a clinician's antibiotic treatment, we used a prospective interrupted time series design to ascertain if a change in antibiotic susceptibility reporting for UTI to community clinicians by a microbiology department for agents with a similar prevalence of resistance (from co-amoxiclav to cefalexin) would lead to a change in clinician's antibiotic prescribing patterns for laboratory investigated UTIs and all other UTIs. Seeing an antibiotic listed on susceptibility reports for UTIs may subconsciously influence a clinician's prescribing for other infections. Therefore, in this study we also determined the effect of the intervention on prescribing for all infections.
Methods

Study design
We used a prospective interrupted time series study of the effects of changing antibiotic susceptibility reporting to GPs. By using an interrupted time series study we could collect multiple observations over time that were 'interrupted' by an intervention and determine whether the intervention had a significant effect, allowing for seasonal trends.
Study location
The study included general practices served by the Southmead Microbiology Laboratory (Southmead), North Bristol Trust, Bristol, England. Practices were excluded from the study if they were involved in research regarding UTI prescribing during the data collection period.
Laboratory reporting of antibiotic susceptibility results
Southmead used the Health Protection Agency National Standard Methods Standard Operating Procedure (NSOP) 19 and routinely screened for extended-spectrum b-lactamases (ESBLs). Susceptibility to amoxicillin, nitrofurantoin, trimethoprim and co-amoxiclav were routinely reported on primary care urine specimens with cultures of ≥10 5 cfu/mL of a single organism. Co-amoxiclav was not reported if the organism was susceptible to amoxicillin (31%). The antibiotic susceptibility reporting was undertaken using a computer rule-base.
Intervention
One of the routinely reported antibiotic susceptibilities for primary care UTI reports was changed: susceptibility to cefalexin was reported in place of susceptibility to co-amoxiclav. This change in reporting was purely for the purposes of the study and was not in response to changing resistance rates or requests from GPs. Routine reporting of amoxicillin, nitrofurantoin and trimethoprim remained unchanged. The intervention ran from 3 July 2006 to 5 March 2007 (9 months) and GPs were not informed of the study. Antibiotic susceptibility reporting was undertaken using a computer rule-base (so was not subject to human error) and was audited twice during the study. The audit used a set of pre-intervention (n ¼100) and post-intervention (n¼173) reports. Cefalexin was not reported in the pre-intervention period, but was included on all reports during the intervention. Co-amoxiclav was reported on 69% of reports pre-intervention and on 2% of reports during the intervention period.
Data collection
We measured antibiotic prescribing in three ways. First, we used a clinician questionnaire survey of antibiotic prescribing for UTIs in which a urine specimen had culture and susceptibility performed. Second, we used a MIQUEST (Morbidity Information Query and Export Syntax, NHS Connecting for Health) software search for antibiotics prescribed to all patients presenting with UTIs (irrespective of laboratory investigation) in a subset of general practices served by the laboratory and randomly selected using a pseudo-random number generator. MIQUEST software was developed by the NHS and is endorsed by the NHS executive. This software facilitates anonymised standardized data extraction from practice computer systems via Read codes. 20 Third, we analysed Prescribing Analysis and Cost (PACT) data for prescribing of selected antibiotics at all general practices served by Southmead. PACT data collected by the Prescription Prescribing Authority consists of all prescriptions issued by GPs that are dispensed by community pharmacists, dispensing GPs or appliance contractors. The information collected includes the name and cost of the drug and the number of items dispensed (an item is defined as each preparation on the prescription). This information is available at the individual practice level, health authority level and national level, allowing different analyses.
Clinician questionnaire survey of antibiotic prescribing for UTIs
A validated questionnaire 21 attached to community midstream urine reports was used to determine clinicians' antibiotic prescribing for urine submitted for culture. This method had previously achieved a questionnaire return rate of 92%. 22 Over the 18 months from August 2005 to February 2007, 1064 questionnaires were sent out to 252 GPs in 33 surgeries at 2 month intervals at five timepoints pre-intervention and four during the intervention (n ¼1064 in total; 500 pre-intervention and 564 during the intervention). At each timepoint, community urine culture reports for different patients with growth .10 5 cfu/mL of any organism(s) were randomly selected using pseudo-random numbers. The questionnaire asked clinicians about the urine report to which it was attached and queried what antibiotic was initially prescribed, whether clinicians changed or commenced antibiotic treatment on receipt of the report and, if they did change antibiotic, what agent was used. 20 For each urine report, anonymised demographic information was also collected on each patient.
Practice antibiotic use for UTI by MIQUEST searches
Only practices using the EMIS LV software system (Egton Medical Information Systems Ltd) and with a stable computerized patient Antibiotic susceptibility reporting to primary care 1397 JAC record system over the study period were included. A total of 23 practices were identified and 7 were randomly selected using pseudo-random numbers. They were initially approached by telephone and asked to provide written consent if they were willing to participate in the study. Practice parameters confirmed that practices included in MIQUEST searches were similar to other practices in the Primary Care Trust (PCT).
A unique MIQUEST search was developed and performed for a 33 month period before the intervention, during the intervention and post-intervention, from 1 June 2005 to 28 February 2008, by the NHS Primary Care Audit Group (SW England). The search identified consultations for urinary symptoms suggesting UTI and identified individual courses of antibiotics (amoxicillin, oral cephalosporins, co-amoxiclav, trimethoprim, nitrofurantoin and quinolones) prescribed within 10 days. An antibiotic prescribed during a consultation within 4 weeks of a previous prescription for a UTI was defined as being a 'second' prescription for a continuing UTI.
PACT data for all practice antibiotic use
The main outcome measure was the total number of antibiotic prescriptions in each practice. This was investigated by collecting PACT data for all surgeries served by Southmead. Data were collected for all oral prescription items of amoxicillin, cephalosporins, co-amoxiclav, trimethoprim, nitrofurantoin and quinolones within a practice. Data were collected for the 24 
Sample size Clinician questionnaire survey
A previous GP questionnaire survey of general practices served by laboratories across England and Wales found 8% of those GPs who were served by laboratories that reported cephalosporins also prescribed these antibiotics empirically to patients with urinary symptoms, compared with 2% of GPs served by laboratories that did not report cephalosporins (P,0.01). 20 We therefore estimated that a sample size of 300 questionnaire responses in the periods before and during the intervention would allow us to detect with 90% confidence a 6% change in empirical cephalosporin prescribing, from 2% before to 8% during the intervention.
MIQUEST searches
A detailed audit of one practice served by Southmead prior to the study period showed that there were 548 consultations for suspected UTI per 10000 patient population per year and confirmed bacteriuria cases per year were 350/10000 patients. Therefore, recruiting seven practices would identify at least 440 cases of UTI per quarter. Comparing the outcomes in just one-quarter pre-and post-intervention, there was .90% confidence of detecting a 6% change in prescribing if the initial percentage prescribing was ,4%.
Data analysis
The assessment of the change in prescribing during the intervention compared with before and after was performed using mixed-effects logistic regression models. For the three studies, the outcome variable was whether a particular antibiotic was prescribed. We examined prescriptions of antibiotics that could be prescribed for UTI (amoxicillin, oral cephalosporins, co-amoxiclav, trimethoprim, nitrofurantoin and quinolones), as changing reporting of co-amoxiclav may have influenced prescriptions of the other choices available to GPs. For the clinician questionnaire survey and the MIQUEST searches this was a binary variable, while for the PACT data, the total number of prescriptions was supplied and this was used as a binomial proportion. To allow for the potential dependencies of prescribing between GP practices, a random effect for practice was included in all models. This random effect was assumed to have a Gaussian distribution. The intervention was included as either a two-or three-level categorical predictor variable (pre-intervention, during intervention and post-intervention), depending upon whether there were data available after the intervention ceased. To allow for seasonal patterns in antibiotic prescriptions, a four-level categorical variable-summer (Jun-Aug), autumn (Sep-Nov), winter (Dec-Feb) and spring (Mar-May)-was included as a predictor variable in all models. For the three data sources, a small number of additional predictors that may influence antibiotic prescription or antibiotic resistance were included in the model. Clinician questionnaire survey, the patients age and whether the prescription was made prior to or when the laboratory report was received were used as additional predictor variables. Interactions between the intervention and when the prescription was made were explored. For the MIQUEST searches, two binary variables-whether the prescription was made for a recurrent infection, and whether it was a 'second' prescription-were also included as fixed effects. The interactions between the intervention and recurrent UTIs and 'second' prescriptions were explored. For PACT data, the amoxicillin prescriptions were not included. The rationale for this model was to reduce contamination in the assessment of the intervention aimed specifically at UTIs from the effect of prescriptions for respiratory infections. Deviance residuals were checked for an approximate Gaussian distribution and to ensure no particular month of prescribing was unusual. The random effects were also checked to ensure they had a Gaussian distribution. Regression models were fitted using Stata 11 (StataCorp LP, College Station, TX).
Ethics approval and consent
Ethics approval was gained from the Southmead NHS Research Ethics Committee (05/Q2002/15). The study was also registered with the Avon Primary Care Research Collaborative R&D Project and approval was given by Bristol North, North Somerset and South Gloucestershire PCTs. Written consent was obtained from the North Bristol Trust R&D and the collective of Avon PCT governance leads.
Results
Resistance rates of primary care E. coli urine isolates to trimethoprim and amoxicillin did not change during the study period (trimethoprim 28.2% before and 29.8% during; amoxicillin 43.2% before and 43.4% after).
Questionnaire survey of laboratory investigated UTIs
During the study period, E. coli was isolated in 76% (n¼ 528) of community UTIs. For reports attached to the questionnaires, resistance rates to co-amoxiclav reported before the intervention and cefalexin reported during the intervention were similar (3% and 3.6%, respectively, P¼ 0.6, x 2 test of association). Seven hundred (66%) of the 1064 questionnaires were returned from 222 healthcare professionals (HCPs) (98% doctors; range of questionnaires returned 1-7; lower quartile 2, upper quartile 4) from 33 practices served by Southmead. Three questionnaires were excluded due to incomplete microbiology results, resulting in 338 analysable questionnaires pre-intervention and 359 (52%) during the intervention. There were no significant differences in factors that may influence resistance rates, including the age of the patients (P¼ 0.5, Mann -Whitney rank sum test) or the UTI bacterial isolates reported to the HCPs before and during the reporting change (P ¼0.13, Fisher's exact test).
Clinicians reported prescribing a total of 735 courses of antibiotics in 653 (94%) of the study patients. Of these, 412 (56%) were prescribed empirically prior to receipt of the laboratory results. Clinician-reported prescriptions of co-amoxiclav fell by more than half, from 55 (14.9%) prescriptions pre-intervention to 19 (5.2%) during the change in laboratory reporting (Figure 1a) . Reported prescriptions of oral cephalosporins increased from being the least commonly prescribed antibiotic before the intervention, with 5 (1.4%) prescriptions, to 42 (11.5%) prescriptions during the intervention. There were no other significant changes in antibiotic prescriptions detected with the questionnaire survey.
In the mixed-effects logistic regression model, the estimated odds ratio (OR) for reported prescriptions of oral cephalosporins was 9.88 [95% confidence interval (CI) 3.00-32.51, P,0.001], increasing by nearly 10-fold after the inclusion of cefalexin on the laboratory report (Table 1) . For co-amoxiclav there was a significant reduction in reported prescriptions during the intervention (estimated OR 0.30; 95% CI 0.16 -0.57, P,0.001). However, the reduction in reported prescribing only occurred once the prescriber was in receipt of the laboratory report. Thus empirical prescribing of co-amoxiclav remained unchanged (OR 0.73; 95% CI 0.33-1.61), whereas first prescriptions after receiving the laboratory report decreased (OR 0.09; 95% CI 0.02-0.44), as did co-amoxiclav prescribed when there was a change in antibiotics after receipt of the report (OR 0.08; 95% CI 0.02-0.41).
MIQUEST searches of GP antibiotic prescriptions for UTI
During the 33 month data collection period there were 8550 Read coded antibiotic prescriptions for 6762 episodes of UTI in 4593 patients in the seven GP practices (range 283 -1943 prescriptions). About two-thirds of these patients (2829, 62%) were given an antibiotic prescription for a single UTI and 1979 (23%) patients received a prescription for recurrent UTIs. A second antibiotic prescription within 4 weeks occurred for 1788 (21%) prescriptions. Trimethoprim was mainly prescribed for first episodes of infection and nitrofurantoin was mainly given for second or recurrent episodes (Table S1 , available as Supplementary data at JAC Online).
The prescribing of cefalexin increased from 4.9% of prescriptions for UTI to 7.5% (OR 1.5; 95% CI 1.18-1.95, P ¼ 0.001) during the intervention period, whereas co-amoxiclav prescriptions decreased from 6.4% to 5.1% (OR 0.75; 95% CI 0.58-0.97, P ¼ 0.03). Table 2 and Figure 1(b) show that prescribing reverted to pre-intervention levels after the reporting change ended. The mixed-effects logistic regression analysis indicated that both antibiotics were more than twice as likely to be prescribed as 'second' antibiotics (cefalexin second prescriptions OR 2.18; 95% CI 1.44 -3.30, P,0.001 and co-amoxiclav OR 2.44; 95% CI 2.01-2.97). Table 2 shows that these changes in prescribing were not due to seasonal differences. There was a significant interaction between the intervention and 'second' prescriptions for cefalexin but not for co-amoxiclav. During the intervention, 'second' prescriptions of cefalexin increased, but there was no significant increase in initial antibiotic prescriptions (OR 1.22; 95% CI 0.892-1.672, P ¼ 0.2). After the intervention was removed, cefalexin prescriptions returned to preintervention levels, regardless of whether it was for initial or 'second' prescriptions [OR 1.186 (P ¼0.2) and 1.042 (P ¼ 0.8), respectively].
Ciprofloxacin prescribing decreased by one-third during the intervention (OR 0.66; 95% CI 0.485-0.897, P ¼ 0.008). After, but not during the intervention, prescribing of cefradine Antibiotic prescribing for all infections determined using PACT data
The overall prescribing of cefalexin measured by PACT data increased by 20% during the intervention (comparing preintervention and during intervention, OR 1.20; 95% CI 1.12 -1.30, P,0.001) ( Table 3 ). Figure 1(c) shows the gradual increase in prescribing over the 9 months of the intervention period. In the 4 months post-intervention the mixed-effects logistic regression analysis showed that cefalexin prescriptions continued to be significantly increased. The prescribing of co-amoxiclav decreased by 8% during the intervention (OR 0.92; 95% CI 0.89 -0.96, P,0.001) and continued to be significantly decreased during the 4 months of data collection post-intervention (Table 3) .
There is some weak evidence that prescriptions for all oral cephalosporins increased by 4% during the intervention (OR 1.04; 95% CI 1.00-1.09, P ¼0.05). These data also indicated some differences in prescriptions for antibiotics not involved in the intervention. Prescriptions of nitrofurantoin increased both during (OR 1.12; 95% CI 1.06 -1.19, P,0.001) and after the intervention (OR 1.20; 95% CI 1.11 -1.30, P,0.001).
Discussion
Main findings
This study provides more evidence that changing laboratory antibiotic susceptibility reporting has a direct effect on antibiotic prescribing by GPs. Cefalexin and cephalosporin use increased when cefalexin was reported and co-amoxiclav prescribing decreased when co-amoxiclav was not reported by the laboratory. MIQUEST data indicated that prescribing reverted to preintervention levels once the change in antibiotic reporting had stopped. First-line use of trimethoprim did not change during the intervention. Our data indicate that much of the change in prescribing can be attributed to second-line use of cefalexin and co-amoxiclav for persistent or recurrent infections, for UTIs confirmed on culture, or for UTIs found to be resistant to the empirical antibiotic prescribed after receipt of a urine antibiotic susceptibility report. The increase in overall cephalosporin use we believe can be explained by clinicians using the cephalosporin that they are familiar with or is on their practice formulary rather than specifically cefalexin that was reported. The intervention also had some inexplicable effects on prescribing of other antibiotics. Ciprofloxacin prescribing decreased during the intervention; this may be because, in UTI, clinicians use ciprofloxacin in similar circumstances to co-amoxiclav and, as co-amoxiclav was not reported, they also did not use ciprofloxacin. The McNulty et al.
increase in nitrofurantoin use may be because clinicians were using a reported antibiotic with which they were more familiar.
Strengths of the study
This is the first prospective longitudinal interventional study examining the influence of laboratory antibiotic susceptibility reporting on GP antibiotic prescribing. Moreover, the antibiotic prescribing data were collected from three different sources, adding robustness to our findings.
Weakness of the study
We did not have control practices that continued with the same antibiotic reporting during the intervention period, as this would have been impossible for the participating laboratory to undertake with their present computer system. Therefore, we cannot say with absolute certainty that the reporting change caused the antibiotic prescribing changes. However, there were no other educational interventions during this period and prescribing returned to preintervention levels when the intervention stopped. An alternative method could have been to select another laboratory to act as a control. However, other confounding biases may have affected results (e.g. differences in antibiotic guidance, education and reporting practices). Some may criticize us for reporting cephalosporins during the intervention, even though we are advising clinicians to reduce their use. The intervention was undertaken in 2006, before the increase in community Clostridium difficile and before cefalexin replaced co-amoxiclav, which probably has similar risks associated with C. difficile. Although the questionnaire return rate was high for this sort of study, 66%, and we received questionnaire returns from all 33 practices served by the laboratory, there still may have been some selection bias in the questionnaire results, as we do not know what would have been prescribed for 34% of UTI episodes in which questionnaires were not returned. We only collected PACT data for a single quarter post-intervention, therefore we do not know if prescribing would have returned to previous prescribing rates. Ideally we would have continued to collect questionnaire and PACT data for a longer time period. However, due to the time it took to develop the MIQUEST search criteria and organize the searches with GPs, the MIQUEST data were only available for a year post-intervention and the results from these data indicate that prescribing for UTIs reverted to pre-intervention levels after cefalexin was not reported. We cannot rule out that the questionnaires may have Note: UTI episodes were defined for MIQUEST data analysis based on time between consultations and/or antibiotic prescriptions; enabling antibiotic prescriptions given for recurrent and continuing UTI episodes to be considered separately. A prescription issued to a patient during a reconsultation within 4 weeks of a previous prescription for a UTI was defined as a 'second' prescription for the same continuing UTI episode.
Antibiotic susceptibility reporting to primary care 1401 JAC influenced clinicians prescribing; however, the MIQUEST data indicate that the 700 questionnaires collected from the 33 practices were only a minority of the total treated over the time period, as 6500 episodes of UTI were identified in the seven practices involved in the MIQUEST search. In addition, the MIQUEST data collected in those time periods post-intervention (when questionnaires were not distributed) showed that clinicians reverted to their previous prescribing habits without the influence of questionnaires. The change in reporting protocol only ran for 9 months. During this time the PACT data showed a gradual increase in cefalexin use. If the intervention had continued, this gradual increase in cefalexin may have continued as clinicians' familiarity with the antibiotic increased, however, we have no direct evidence for this. We do not suggest that either co-amoxiclav or cefalexin are routinely reported by laboratories for UTIs. Our study was designed to demonstrate the influence of reporting antibiotic susceptibilities and the impact this has on the use of these agents. Indeed, the effect of changing reporting policies may have been greater if the antibiotic reporting change had included trimethoprim or nitrofurantoin, which were used more frequently than co-amoxiclav.
Other work in this area
Other hospital-based studies have indicated an association between reporting of antibiotic susceptibility results and their use. Cunney et al. 23 found that antibiotics were twice as likely to be prescribed in the hospital setting if antibiotic susceptibilities were reported for sputum, urine and wound cultures. Interestingly, a study across the European Union showed that acute care hospitals that routinely reported susceptibility results for restricted antibiotics had significantly lower median total antibiotic use in 2001. 24 Steffee et al. 25 found that there was a significantly increased use of rifampicin for hospitalized patients when the microbiology laboratory started reporting rifampicin for all Gram-positive bacterial isolates. Stopping reporting of rifampicin did lead to a decrease in rifampicin use, but this change was accompanied by other antibiotic stewardship advice and interventions. 25 Our intervention was not accompanied by any other advice or educational intervention and clinicians were not informed of the reporting change.
Regardless of the clinical indications, if antibiotic susceptibilities are on laboratory culture reports, clinicians are more likely to consider that the organism reported warrants antibiotic treatment and will prescribe one of the antibiotics listed. A primary care study showed that when an antibiotic susceptibility was reported for organisms cultured from leg ulcer swabs, primary care clinicians reported that they would be more likely to prescribe an antibiotic (58% versus 16%, P,0.001).
26
Implications of this work
Antibiotic susceptibility reporting on UTI organisms by laboratories to primary care physicians is not standardized across the Note: Other antibiotics included in analysis were other oral cephalosporins, trimethoprim, nitrofurantoin and quinolones. Amoxicillin was excluded to limit the impact of seasonal variation in prescribing patterns.
UK or Europe. 18, 24 Although the majority of laboratories report trimethoprim, amoxicillin and nitrofurantoin, as these are the agents most commonly prescribed by clinicians for UTIs, in 2001 many laboratories still routinely reported a cephalosporin and 13% routinely reported co-amoxiclav, while a minority of laboratories reported a quinolone. 18 Our results suggest that the National SOPs should discourage the use of reporting broadspectrum agents to primary care physicians if another narrower agent is appropriate. As other work has indicated, if an association between antibiotic use and antibiotic susceptibility is also true for other specimens, then this policy should not just apply to urine specimen reports, but should be considered for all specimen types. 23, 25, 26 Microbiology laboratories should be keenly aware of the direct influence their antibiotic susceptibility reporting protocols have on GP antibiotic prescribing, both for UTIs and in other specimens. With the high throughput of specimens in the laboratory, it is easier to report all antibiotics tested to GPs and rely on the clinician to choose an appropriate agent. However, if the laboratory wishes to influence antibiotic use, we need to consider which antibiotics we should routinely report. Regular audits of laboratory antibiotic susceptibility reporting to GPs would be useful. With the increase in community-onset methicillinresistant Staphylococcus aureus (MRSA), C. difficile and ESBLproducing E. coli, it has become increasingly important to reduce the use of co-amoxiclav and avoid the use of cephalosporins and quinolones in situations where other antibiotics could be equally effective. We suggest that two or three narrowspectrum agents should be routinely reported for UTIs, in line with national 27 or local antibiotic guidelines. A second-line agent can then be reported if the organism reported is resistant to both of these antibiotics.
Within general practices, clinicians need to be made aware that when an antibiotic susceptibility is reported it does not necessarily mean that an antibiotic is always needed. Laboratories could assist in educating clinicians by adding suitable comments to reports or providing website links to local or national antibiotic prescribing or diagnostic advice on electronic reports. 27 
